These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11556191)

  • 1. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
    MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
    [No Abstract]   [Full Text] [Related]  

  • 2. [Organ protection in hypertensive type 2 diabetic patients. Double chance with AT1 blockers].
    MMW Fortschr Med; 2000 Jan; 142(3):58-9. PubMed ID: 10726465
    [No Abstract]   [Full Text] [Related]  

  • 3. [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910830
    [No Abstract]   [Full Text] [Related]  

  • 4. [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
    Bold KO
    MMW Fortschr Med; 2001 May; 143(22):12-3. PubMed ID: 11460392
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evidence based treatment of diabetic nephropathy].
    Sugimoto T
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():294-300. PubMed ID: 12430244
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EC approves irbesartan for the treatment of diabetic renal disease.
    Cardiovasc J S Afr; 2002; 13(4):216-7. PubMed ID: 12402931
    [No Abstract]   [Full Text] [Related]  

  • 8. Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
    Cardiovasc J S Afr; 2001; 12(4):242-3. PubMed ID: 11766619
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prospective treatment study of irbesartan. Diabetic kidneys regain function].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145(41):41. PubMed ID: 14655481
    [No Abstract]   [Full Text] [Related]  

  • 10. A new class of antihypertensive: angiotensin II receptor antagonists.
    McCoy R
    S D J Med; 1995 Sep; 48(9):319-20. PubMed ID: 7481726
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug companies should not have the final say in the design of clinical trials.
    Kurtzman NA
    Am J Kidney Dis; 2001 Nov; 38(5):1113-4. PubMed ID: 11684568
    [No Abstract]   [Full Text] [Related]  

  • 12. Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
    Cardiovasc J S Afr; 2001; 12(4):240-1. PubMed ID: 11766617
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
    MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Walser M
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873778
    [No Abstract]   [Full Text] [Related]  

  • 15. [Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].
    MMW Fortschr Med; 2003 Apr; 145(17):55. PubMed ID: 12808810
    [No Abstract]   [Full Text] [Related]  

  • 16. Candesartan in the treatment of hypertension: what have we learnt in the last decade?
    Barrios V; Escobar C
    Expert Opin Drug Saf; 2011 Nov; 10(6):957-68. PubMed ID: 21848481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II receptor blockers and nephropathy trials.
    Bloomgarden ZT
    Diabetes Care; 2001 Oct; 24(10):1834-8. PubMed ID: 11574450
    [No Abstract]   [Full Text] [Related]  

  • 18. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible ageusia associated with losartan.
    Schlienger RG; Saxer M; Haefeli WE
    Lancet; 1996 Feb; 347(8999):471-2. PubMed ID: 8618505
    [No Abstract]   [Full Text] [Related]  

  • 20. [Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
    de Alvaro F
    Nefrologia; 2001; 21 Suppl 3():76-82. PubMed ID: 11642211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.